Dihexa
Also known as: PNB-0408
Dihexa (PNB-0408) is a small-molecule hexapeptide-like analog of angiotensin IV developed at Washington State University by the Harding/Wright group as a preclinical candidate for Alzheimer's disease and cognitive decline. It is NOT FDA-approved and has never been tested in human clinical trials. The often-quoted claim that it is 'roughly ten million times more potent than BDNF' refers to EC50 comparisons in an in vitro dendritic spine assay, not clinical efficacy.
Pricing for Dihexa
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Dihexa
3 third-party tests across 2 vendors. Each card links to the full report.
For
Dihexa
by Moglabs· batch DIH001
For
Dihexa
by BioLongevity Labs· batch cmojb7lwg01cqkirxjd6royw0
Purity not on file
For
Dihexa
by Skye Peptides· batch 01DXA25
12 citations indexed for Dihexa
review · 2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.
Study · 2026
Umbilical cord mesenchymal stromal cells-derived HGF inhibits STING-mediated pyroptosis to alleviate cerebral ischemia/reperfusion injury via c-Met/β-catenin/RNF5 pathway
in-vitro · 2025
Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells
The growth factor and small molecule protocol are the two primary approaches for generating human induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs). We compared the efficacy of the growth factor and small molecule protocols across fifteen different human iPSC lines.
animal · 2025
Generation and applications of an expandable and mature hiPSC-derived liver organoid
Organoids have emerged as a powerful tool for modeling liver diseases, drug screening, and personalized treatments. However, they have a limited capacity to generate functional hepatocytes in a reproducible and efficient manner.
Study · 2025
The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories
In recent years, an increasing number of case reports have mentioned the presence of illicit nootropics, smart drugs or mind doping products on the market.
animal · 2024
Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats
Background Huntington's disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric dysfunction caused by a mutant huntingtin protein.